Amoéba Secures Its First Order from Global Biocontrol Leader Koppert
Amoéba has received its first order from Koppert, the global leader in biocontrol, as part of the distribution agreement signed in June 2025. This order marks the official entry of the greentech into the commercial phase and will be delivered starting April 2026.
The order is part of the distribution agreement signed with Koppert in June 2025. This agreement covers vineyards and vegetable crops in 18 European countries and the United States. The initial deliveries of this order will be made starting in April 2026 and will help build the necessary inventory to meet demands in France, Italy, and the Netherlands.
Structuring Agricultural Activities
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Amoéba is now structuring its agricultural activities around its subsidiary Green 4 Agro, which is wholly owned by Amoéba. This subsidiary is dedicated to the marketing and development of biofungicides and biostimulants. Jean-Marc Petat, a former administrator at Amoéba, has been leading it since March 1, 2026. He brings nearly 30 years of experience from the BASF group in the agricultural and biocontrol sectors.
Launch of TIAGAN and Ongoing Collaboration
Amoéba and Koppert launched TIAGAN at the beginning of the year, the commercial name for Amoéba's solution aimed at the vineyard market. The two companies continue their joint work phase to determine the best offers to address the various markets covered by their agreement. Martin Koppert, Commercial Director of Koppert, emphasized that the company has adopted a gradual approach to properly target the territories and crops that will be prioritized before scaling up.
Sur la base de ses ressources actuelles, de son plan d'affaires et de la lettre de soutien de son actionnaire de référence, Amoéba estime pouvoir faire face à ses obligations jusqu'au 31 décembre 2026.
Risks mentioned
Autorisation définitive d'AXPERA obtenue tardivement (fin juin 2026) après période d'utilisation des produits, affectant les ventes du semestre
Monétisation de la plateforme cosmétique dont ni la réalisation, ni le calendrier, ni le montant ne sont acquis à ce jour
Besoin de levée de fonds supplémentaire pour assurer continuité d'exploitation jusqu'au 30 septembre 2027 et financer plan de développement
Opportunities identified
Autorisation pérenne AXPERA obtenue en France en juin 2026 ouvre la voie à la commercialisation en plusieurs pays européens
Accord majeur signé avec Syngenta pour distribution exclusive de la solution en céréales dans 27 pays UE, premiers lancements commerciaux attendus Q3 2028
Extension de l'accord de distribution Koppert jusqu'en juin 2031 et potentiel de monétisation de la plateforme cosmétique Willa™ dès 2027
Outlook / guidance
Expected revenue: 1,5 millions d'euros
Management commentary: Building on the outcomes of the various strategic initiatives undertaken since 2023, Amoéba will be able to leverage the ramp-up of its contracts in the agricultural sector from 2027 onwards to achieve revenue of between €1 million and €2 million.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
